 Marinus Pharmaceuticals NASDAQ: MRNS shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment of CDKL5 deficiency disorder.Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics.The company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.Marinus Pharmaceuticals shares were trading up 6.29 at 1.69 at time of publication on Thursday. The stock has a 52-week high of 3.50 and a 52-week low of 1.01.See more from Benzinga Why Chevrons Stock Is Trading Lower Today Why Goldman Sachs Is Trading Lower Today US GDP Plunges 32.9 In Historic Q2 Contraction Fueled By Coronavirus PandemicC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 